clinical trial · NCT06433765
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Multiple SclerosisNo intervention
brief summary
The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.
started
Jun 1, 2024
primary completion
Mar 31, 2035
completion
Mar 31, 2035
last updated
Apr 3, 2026
official title
BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol